Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRCA Verrica Pharmaceuticals Inc.

Trading 03-28 13:20:38 EDT

0.4311

-0.0064

-1.46%

High0.4698	Low0.4193	Vol118.88K
Open0.4375	D1 Closing0.4375	Amplitude11.54%
Mkt Cap39.57M	Tradable Cap14.74M	Total Shares91.78M
T/O51.53K	T/O Rate0.35%	Tradable Shares34.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VRCA","market":"US","secType":"STK","nameCN":"Verrica Pharmaceuticals Inc.","latestPrice":0.4311,"timestamp":1743182429506,"preClose":0.4375,"halted":0,"volume":118880,"delay":0,"floatShares":34185569,"shares":91779993,"eps":-1.478124,"marketStatus":"Trading","change":-0.0064,"latestTime":"03-28 13:20:38 EDT","open":0.4375,"high":0.4698,"low":0.4193,"amount":51528.1508288,"amplitude":0.115429,"askPrice":0.433,"askSize":10,"bidPrice":0.4303,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-1.478124,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1529035200000,"exchange":"NASDAQ","adjPreClose":0.4375,"postHourTrading":{"tag":"盘后","latestPrice":0.4699,"preClose":0.4375,"latestTime":"18:48 EDT","volume":978,"amount":435.8751,"timestamp":1743115713187},"volumeRatio":0.213846,"impliedVol":0.7231,"impliedVolPercentile":0.428},"requestUrl":"/m/hq/s/VRCA","defaultTab":"news","newsList":[{"id":"2522820730","title":"Press Release: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820730","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820730?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"WEST CHESTER, Pa., March 26, 2025  -- Verrica Pharmaceuticals Inc.  , a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.\"We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer,\" said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. \"As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH as the new standard of care for the treatment of molluscum contagiosum and advance our clinical-stage programs in basal cell carcinoma and common warts. Dr. Rosenberg brings to Verrica more than 30 years of clinical and therapeutic development experience with multiple global drug approvals across a number of therapeutic areas, including dermatology.\". Dr. Rosenberg has served as Chief Medical Officer for both ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4232","NQmain","BK4135","NOAH","BK4022","VRCA","BK4588","BK4531","R","BK4007"],"gpt_icon":0},{"id":"2518068517","title":"Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2518068517","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518068517?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 15:08","pubTimestamp":1741763292,"startTime":"0","endTime":"0","summary":"Total Revenue : $0.3 million, primarily from YCA sales.Total Revenue : $7.6 million, up from $5.1 million in 2023.Net Product Revenue : $6.6 million, compared to $4.7 million in 2023.Research and Development Expenses : $1.2 million, decreased by $4.2 million from Q4 2023.Research and Development Expenses : $11.8 million, down from $20.3 million in 2023.Selling, General and Administrative Expenses : $10 million, decreased by $6.8 million from Q4 2023.GAAP Net Loss : $16.2 million or $0.24 per share.Non-GAAP Net Loss : $64.6 million or $1.25 per share.YCA Dispense Applicator Units : 8,654 units, a 12.3% increase from Q3 2024.GuruFocus has detected 5 Warning Signs with VRCA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Verrica Pharmaceuticals Inc  reported a GAAP net loss of $16.2 million for Q4 2024, reflecting ongoing financial challenges.The company's total revenues for Q4 2024 were only $0.3 million, indicating limited revenue gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-q4-070812219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRCA"],"gpt_icon":0},{"id":"2518705195","title":"Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2518705195","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518705195?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:25","pubTimestamp":1741728305,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc.  came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.49, delivering a surprise of -32.43%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Verrica Pharmaceuticals , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.34 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 80.78%. This compares to year-ago revenues of $1.99 million. The company has topped consensus revenue estimates two times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-reports-212505549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRCA"],"gpt_icon":0},{"id":"2518777867","title":"Verrica Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2518777867","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518777867?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:09","pubTimestamp":1741727390,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryVerrica Pharmaceuticals Inc VRCA.OQ reported a quarterly adjusted loss of 24 cents per share for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU2HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA"],"gpt_icon":0},{"id":"2518777419","title":"Verrica Pharmaceuticals Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2518777419","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518777419?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:06","pubTimestamp":1741727186,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU1EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2518771198","title":"Verrica Pharmaceuticals Q4 2024 Adj. EPS $(0.18) Beats $(0.26) Estimate, Sales $344.000K Miss $1.041M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518771198","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518771198?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:12","pubTimestamp":1741723927,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.26) by 30.77 percent.  The company reported quarterly sales of $344.000 thousand which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44262440/verrica-pharmaceuticals-q4-2024-adj-eps-0-18-beats-0-26-estimate-sales-344-000k-miss-1-041m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Verrica Pharmaceuticals Q4 2024 Adj. EPS $(0.18) Beats $(0.26) Estimate, Sales $344.000K Miss $1.041M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA"],"gpt_icon":0},{"id":"2518700427","title":"Corrected-Verrica Pharmaceuticals Q4 Collaboration Revenue USD 29 Thousand (Corrects Amount)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518700427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518700427?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:05","pubTimestamp":1741723502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nPLX7FBB65:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2518545771","title":"Verrica Pharmaceuticals Q4 Basic EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2518545771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518545771?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:05","pubTimestamp":1741723502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nPLX7FBB65:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2518373771","title":"Verrica Pharmaceuticals Q4 Collaboration Revenue USD 315 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2518373771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518373771?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:05","pubTimestamp":1741723502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nPLX7FBB65:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2518506772","title":"Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518506772","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518506772?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:05","pubTimestamp":1741723500,"startTime":"0","endTime":"0","summary":"– Company generated quarterly sequential growth in YCANTH dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses –。– Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 –。–Late-stage pipeline continues to advance with programs in basal cell carcinoma  and common warts  –。–Recently strengthened balance sheet with the November 2024 $42 million public offering –。WEST CHESTER, Pa., March 11, 2025  -- Verrica Pharmaceuticals Inc.  , a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and full year ended December 31, 2024.The Company will host a conference call today, Tuesday, March 11, 2025, at 4:30 PM, Eastern Time, to discuss its fourth quarter and year-end 2024 financial results and pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verrica-pharmaceuticals-reports-fourth-quarter-200500552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2517382534","title":"Verrica Pharmaceuticals Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517382534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517382534?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:34","pubTimestamp":1741354463,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc  expected to post a loss of26cents a share - Earnings Preview Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a fall in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ17P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA"],"gpt_icon":0},{"id":"2516706687","title":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516706687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516706687?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"WEST CHESTER, Pa., March 03, 2025  -- Verrica Pharmaceuticals Inc.  , a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update.Individuals may participate in the live call via telephone by dialing 1-800-445-7795  or 1-785-424-1699  and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verrica-pharmaceuticals-report-fourth-quarter-120000308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2514828253","title":"Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514828253","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514828253?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 23:00","pubTimestamp":1740668419,"startTime":"0","endTime":"0","summary":"Wall Street expects a year-over-year increase in earnings on lower revenues when Verrica Pharmaceuticals Inc.  reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +47.9%.Revenues are expected to be $1.79 million, down 10.1% from the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-expected-150019038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS","VRCA"],"gpt_icon":0},{"id":"2513270729","title":"Verrica Pharmaceuticals Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2513270729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513270729?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:39","pubTimestamp":1740404349,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc  expected to post a loss of26cents a share - Earnings Preview Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a fall in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL5N3PF18M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA"],"gpt_icon":0},{"id":"2513108612","title":"Verrica Pharmaceuticals - Waiver Includes Requirements That There Be No 'Going Concern' Qualification for 2024 and Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513108612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513108612?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 05:22","pubTimestamp":1740172938,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC19R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2506859896","title":"Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2506859896","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506859896?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 19:41","pubTimestamp":1737718910,"startTime":"0","endTime":"0","summary":"Last week, Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) stock jumped 14%, but insiders who sold US$1.1m worth of stock...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrca/verrica-pharmaceuticals/news/shareholders-cant-ignore-us11m-of-sales-by-verrica-pharmaceu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VRCA"],"gpt_icon":0},{"id":"2505229387","title":"Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of Vp-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2505229387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505229387?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 20:00","pubTimestamp":1737460804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUA1LZJVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2501273008","title":"Verrica Pharmaceuticals Inc : Jefferies Cuts Target Price to $3 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2501273008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501273008?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 18:04","pubTimestamp":1736244269,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O310S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2493642071","title":"Needham Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493642071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493642071?lang=en_us&edition=full_marsco","pubTime":"2024-12-21 02:43","pubTimestamp":1734720201,"startTime":"0","endTime":"0","summary":"In a report released today, Serge Belanger from Needham maintained a Hold rating on Verrica Pharmaceuticals (VRCA – Research Report). The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-their-hold-rating-for-verrica-pharmaceuticals-vrca?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-their-hold-rating-for-verrica-pharmaceuticals-vrca?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRCA"],"gpt_icon":0},{"id":"2492559414","title":"Verrica Pharmaceuticals Inc: Seeing Favorable Changes in Demand Dynamics for Ycanth","url":"https://stock-news.laohu8.com/highlight/detail?id=2492559414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492559414?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 20:00","pubTimestamp":1734696000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA9W22VN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.verrica.com","stockEarnings":[{"period":"1week","weight":-0.2827},{"period":"1month","weight":-0.3557},{"period":"3month","weight":-0.3607},{"period":"6month","weight":-0.7411},{"period":"1year","weight":-0.9226},{"period":"ytd","weight":-0.375}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.09626},{"month":2,"riseRate":0.571429,"avgChangeRate":0.080901},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.059339},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.027247},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.174718},{"month":6,"riseRate":0.5,"avgChangeRate":0.076907},{"month":7,"riseRate":0.428571,"avgChangeRate":0.00496},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.050152},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.059035},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.077378},{"month":11,"riseRate":0.428571,"avgChangeRate":0.042877},{"month":12,"riseRate":0.428571,"avgChangeRate":0.036955}],"exchange":"NASDAQ","name":"Verrica Pharmaceuticals Inc.","nameEN":"Verrica Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Verrica Pharmaceuticals Inc.(VRCA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Verrica Pharmaceuticals Inc.,VRCA,Verrica Pharmaceuticals Inc.股票,Verrica Pharmaceuticals Inc.股票老虎,Verrica Pharmaceuticals Inc.股票老虎国际,Verrica Pharmaceuticals Inc.行情,Verrica Pharmaceuticals Inc.股票行情,Verrica Pharmaceuticals Inc.股价,Verrica Pharmaceuticals Inc.股市,Verrica Pharmaceuticals Inc.股票价格,Verrica Pharmaceuticals Inc.股票交易,Verrica Pharmaceuticals Inc.股票购买,Verrica Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Verrica Pharmaceuticals Inc.(VRCA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction